ValiRx ValiRx ValiBio ValiTherma ValiMedix
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
Shareholders Information
Live Quote
 
 
Aim Rule 26 Admission Document Advisors and Bankers Annual Reports Constitutional Document Corporate Governance Shareholders Information Shares in Issue Stock Information  

2009   

General Meeting Results December 2009

Chairman's Letter December 2009   

Notice of General Meeting December 2009    

AGM Result 2009   

AGM Notice July 2009   

General Meeting Result 2009   

Chairman's Letter 2009   

Notice of General Meeting February 2009   

   

2008    

ValiRx held its last Annual General Meeting on 28 July 2008 in London. The notice together with the Chairman's letter have been sent to shareholders and are also available for download by clicking below    

AGM Result 2008  

AGM Notice 2008   

Form of Proxy 2008   

General Meeting Result 2008   

Chairman's Letter 2008   

Notice of General Meeting 2008   

    

2007    

ValiRx held its first Annual General Meeting on 27th July 2007 in London. The notice of AGM together with the financial accounts for 2006 have been sent to shareholders and are also available for download by clicking on the links in PDF version:-    

AGM Result 2007   

AGM Notice 2007   

Form of Proxy 2007   

Notice to Shareholders 2007